Recent News

• 03.10.2025 - Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
• 03.07.2025 - Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
• 03.03.2025 - Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
• 02.28.2025 - Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
• 02.24.2025 - Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
• 02.19.2025 - JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Recent Filings

• 03.10.2025 - 8-K Current report
• 03.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.10.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 8-K Current report
• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - EFFECT Notice of Effectiveness
• 02.04.2025 - CORRESP Correspondence
• 02.04.2025 - UPLOAD SEC-generated letter